Related Experiment Video
Updated: Mar 8, 2026
08:49
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
9.6K
Allosteric "beta-blocker" isolated from a DNA-encoded small molecule library
Seungkirl Ahn1, Alem W Kahsai1, Biswaranjan Pani1
1Department of Medicine, Duke University Medical Center, Durham, NC 27710.
Summary
Researchers discovered a novel small molecule, compound 15, that acts as a negative allosteric modulator for the beta-2 adrenergic receptor (β2AR). This finding opens new avenues for developing targeted G-protein-coupled receptor (GPCR) drugs with unique allosteric mechanisms.
Area of Science:
- Pharmacology
- Biochemistry
- Drug Discovery
Background:
- The beta-2 adrenergic receptor (β2AR), a G-protein-coupled receptor (GPCR), is crucial in cardiovascular and pulmonary functions.
- Current β2AR drugs target the orthosteric site, limiting therapeutic options.
Purpose of the Study:
- To discover allosteric ligands for the β2AR using DNA-encoded small-molecule libraries.
- To characterize the novel allosteric modulator's mechanism and effects.
Main Methods:
- Screening of 190 million DNA-encoded compounds against purified human β2AR.
- Characterization of compound 15's binding affinity and allosteric modulation.
- Cell-based signaling assays measuring cAMP production and β-arrestin recruitment.
Main Results:
- Discovery of compound 15, a novel negative allosteric modulator with low micromolar affinity for β2AR.
- Compound 15 enhances inverse agonist binding and inhibits agonist binding.
- Compound 15 inhibits β2AR-mediated cAMP production and β-arrestin recruitment.
Conclusions:
- Compound 15 represents a first-in-class allosteric small-molecule ligand for the β2AR.
- The DNA-encoded library screening approach is effective for GPCR drug discovery.
- This method facilitates the development of GPCR drugs with tailored allosteric effects.
Keywords:
DNA-encoded small-molecule libraryG-protein–coupled receptorallosteric modulatordrug discoveryβ2-adrenergic receptorMore Related Videos
Related Concept Videos
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.6K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.8K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.8K
01:08Allosteric Regulation
64.0K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
64.0K
01:28Antihypertensive Drugs: Types of β-Blockers
1.8K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.8K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.1K